Skip to main content
Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc. — Investor Relations & Filings

Ticker · ATXS ISIN · US04635X1028 US Manufacturing
Open in API
Filings indexed 602 across all filing types
Latest filing 2024-06-06 Director's Dealing
Country US United States of America
Listing US ATXS

About Astria Therapeutics, Inc.

https://astriatx.com/

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for allergic and immunologic diseases. The company's mission is to provide life-changing treatments to patients and their families. Its lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein being developed as a potential long-acting, preventative treatment for Hereditary Angioedema (HAE). The company has reported positive initial proof-of-concept results from its ALPHA-STAR Phase 1b/2 clinical trial for STAR-0215. Astria Therapeutics is guided by patient needs to develop differentiated therapeutics that address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-06-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-06-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-06-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-06-06 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 5, 2024, by Astria Therapeutics, Inc. It reports on the Annual Meeting of Stockholders held on the same date. The content includes the election of directors, approval of an amended stock incentive plan, ratification of the independent auditor, and advisory vote on executive compensation. These are all typical disclosures related to changes in board composition and management-related decisions. The document is not a full annual report, earnings release, or financial statement, but rather a current report on significant corporate events, specifically board and management changes and shareholder voting results. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (7084 characters) and detailed voting results support that this is a substantive filing rather than a brief announcement or proxy statement.
2024-06-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-06-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.